MetaADEDB 2.0 @ LMMD
bepotastine
(UDGHXQPQKQPSBB-BOXHHOBZSA-N)
Structure
SMILES
OS(=O)(=O)c1ccccc1.OC(=O)CCCN1CCC(CC1)O[C@H](c1ccccn1)c1ccc(cc1)Cl
Molecular Formula:
C27H31ClN2O6S
Molecular Weight:
547.063
Log P:
6.1222
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
2
TPSA:
125.41
CAS Number(s):
190786-44-8
Synonym(s)
1.
bepotastine
2.
(S)-4-(4-((4-chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid monobenzenesulfonate
3.
TAU 284
4.
TAU-284
5.
betotastine
6.
betotastine besilate
External Link(s)
MeSHC108476
PubChem Compound164521
ChEBI31281
CHEMBLCHEMBL1201759
KEGGdr:D01654
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 8US FAERS
2Eye irritationFAERS: 8
Canada Vigilance: 1		Canada Vigilance
US FAERS
3DysgeusiaFAERS: 5OFFSIDES
US FAERS
4Product taste abnormalFAERS: 4US FAERS
5Throat irritationFAERS: 4US FAERS
6Abdominal discomfortFAERS: 2US FAERS
7KeratitisFAERS: 2US FAERS
8Oropharyngeal painFAERS: 2US FAERS
9PalpitationsFAERS: 2US FAERS
10AcidosisFAERS: 1US FAERS
11AgranulocytosisFAERS: 1US FAERS
12AphoniaFAERS: 1US FAERS
13ArthritisFAERS: 1US FAERS
14AsthmaFAERS: 1OFFSIDES
US FAERS
15Blood creatinine increasedFAERS: 1US FAERS
16Blood glucose increasedFAERS: 1US FAERS
17DysphoniaFAERS: 1US FAERS
18Expired drug administeredFAERS: 1US FAERS
19Eye inflammationFAERS: 1US FAERS
20Eye painFAERS: 1US FAERS
21Fixed eruptionFAERS: 1US FAERS
22HeadacheFAERS: 1US FAERS
23Incorrect route of product administrationFAERS: 1US FAERS
24Instillation site irritationFAERS: 1US FAERS
25LethargyFAERS: 1US FAERS
26MydriasisFAERS: 1US FAERS
27Nephrotic SyndromeFAERS: 1US FAERS
28Retinal DetachmentFAERS: 1US FAERS
29Skin reactionFAERS: 1US FAERS
30SneezingFAERS: 1US FAERS
31Visual acuity reduced transientlyFAERS: 1US FAERS
32treatment failureFAERS: 1US FAERS
33Activities of daily living impairedOFFSIDES
34AlopeciaOFFSIDES
35AlveolitisOFFSIDES
36AnorexiaOFFSIDES
37ApathyOFFSIDES
38AtelectasisOFFSIDES
39Band neutrophil percentage increasedOFFSIDES
40Beta 2 microglobulin urine increasedOFFSIDES
41Blood albumin decreasedOFFSIDES
42BradycardiaOFFSIDES
43Burning sensationCanada Vigilance: 1Canada Vigilance
44Cerebrovascular stenosisOFFSIDES
45Chest PainOFFSIDES
46CholecystitisOFFSIDES
47CryingOFFSIDES
48CryptophthalmosOFFSIDES
49CyanosisOFFSIDES
50Drug exposure during pregnancyOFFSIDES
51Dry skinOFFSIDES
52EczemaOFFSIDES
53EpilepsyOFFSIDES
54EpistaxisOFFSIDES
55Erythema MultiformeOFFSIDES
56ErythemaOFFSIDES
57FlatulenceOFFSIDES
58General physical health deteriorationOFFSIDES
59GlossitisOFFSIDES
60HemothoraxOFFSIDES
61HepatitisOFFSIDES
62HyperventilationOFFSIDES
63IncoherentOFFSIDES
64Leukopenia neonatalOFFSIDES
65Malignant neoplasm progressionOFFSIDES
66Multiple drug overdose intentionalOFFSIDES
67Neutrophil count decreasedOFFSIDES
68OnychoclasisOFFSIDES
69Panic DisorderOFFSIDES
70PleurodesisOFFSIDES
71Productive CoughOFFSIDES
72Protein total decreasedOFFSIDES
73Renal tubular disorderOFFSIDES
74RhinorrheaOFFSIDES
75Skin necrosisOFFSIDES
76Thoracic cavity drainageOFFSIDES
77Upper respiratory tract inflammationOFFSIDES
78Ventricular FibrillationOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.